Project Grant R01FD004809

Novelmed Therapeutics, Inc. was awarded a $900,000 Project Grant from the National Institutes of Health's National Institute on Aging to develop a selective inhibitor of the alternative pathway of complement as a treatment for Neuromyelitis Optica Spectrum Disorder. Under the grant, Novelmed will conduct preclinical studies to evaluate its lead drug candidate NM5072, including in vitro and ex vivo assays to confirm the drug's mechanism of action and selective inhibition of the alternative...

This Project Grant award, totaling $801,359.00 and provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310), will fund a multiple ascending dose, placebo-controlled Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of nicotinamide mononucleotide (NMN) in adults with Down syndrome. The goal is to evaluate NMN as a potential therapeutic to prevent or slow the progression of Alzheimer's disease...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop specialized cryo-electron microscopy (cryo-EM) techniques to study the structures of mitochondrial complexes implicated in muscular myopathies. The $444,109 award to the Scripps Research Institute in La Jolla, CA will support the creation of methods to directly visualize endogenous...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is focused on developing a novel nanovesicle-based therapy for myotonic dystrophy type 1 (DM1), a common adult-onset muscular dystrophy. The $306,859 award supports a two-phase effort to validate interfering RNA-loaded nanovesicles that can selectively modulate the toxic DMPK mRNA responsible for...

This $438,365 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to investigate the role of the CD38 protein and its potential as a therapeutic target for Spinal and Bulbar Muscular Atrophy (SBMA). The research aims to use stem cell technology and CRISPR-corrected isogenic controls to examine metabolic alterations in SBMA patient-derived...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $1,292,847.00 to Advertent Biotherapeutics, Inc. to develop a novel agent called ADA011 for preventing fatty degeneration of muscles in limb girdle muscular dystrophy 2B (LGMD2B). The goal is to demonstrate the long-term efficacy of ADA011 in inhibiting muscle fatty degeneration and...

This $506,198 federal Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) aims to develop platelet-derived exercise mimetics as a potential treatment for Alzheimer's disease and related dementias. The key objectives are to: 1) Generate various clones of the platelet-derived exercise mimetic with improved safety and retained functionality, 2) Optimize the expression and purification of this platelet-derived factor, and 3) Demonstrate that the engineered...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $605,523 to The Trustees of Columbia University in the City of New York, Health Sciences Division, to conduct research on developing therapies that target Purkinje cell synaptic changes to restore circuit function in cerebellar degeneration. The research aims to determine if...

This R01 project grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $6,467,513.00 to Brigham & Women's Hospital Inc. to continue funding for the Ante-Amyloid Treatment of Alzheimer's Disease (A3) Trial and the Alzheimer Plasma Extension (APEX) Study. The A3 Trial is testing low-dose lecanemab, an amyloid-removing monoclonal antibody, in participants with intermediate brain amyloid levels to determine the optimal window for efficacy and safety of...

This federal Project Grant award of $226,435.00 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports a Phase II randomized study to assess the optimal duration of maintenance therapy for patients with light chain (AL) amyloidosis. The study will evaluate the efficacy of 6 months versus 18 months of daratumumab maintenance following initial daratumumab-cybord induction treatment. Key objectives include assessing event-free survival, hematological response,...